* covid-19 diagnosed \> 5 days prior to randomization; * active tuberculosis; * need for concomitant drugs that are contraindicated with the use of chloroquine/hydroxychloroquine; * qtcf interval \> 480 ms; * known glomerular filtration rate \< 10 ml/min; * known with glucose-6-phosphate dehydrogenase deficiency (g6pd); * previous adverse drug reaction to investigational product; * concurrent involvement in other research or use of chloroquine, hydroxychloroquine or any other 4-aminoquinolone or another experimental investigational medicinal product that is likely to interfere with the study medication. note: pregnancy and breastfeeding are not exclusions for entry

* covid-19 diagnosed \> 5 days prior to randomization; * active tuberculosis; * need for concomitant drugs that are contraindicated with the use of chloroquine/hydroxychloroquine; * qtcf interval \> 480 ms; * known glomerular filtration rate \< 10 ml/min; * known with glucose-6-phosphate dehydrogenase deficiency (g6pd); * previous adverse drug reaction to investigational product; * concurrent involvement in other research or use of chloroquine, hydroxychloroquine or any other 4-aminoquinolone or another experimental investigational medicinal product that is likely to interfere with the study medication. note: pregnancy and breastfeeding are not exclusions for entry

- covid-19 diagnosed > 5 days prior to randomization; - active tuberculosis; - need for concomitant drugs that are contraindicated with the use of chloroquine/hydroxychloroquine; - qtcf interval > 480 ms; - known glomerular filtration rate < 10 ml/min; - known with glucose-6-phosphate dehydrogenase deficiency (g6pd); - previous adverse drug reaction to investigational product; - concurrent involvement in other research or use of chloroquine, hydroxychloroquine or any other 4-aminoquinolone or another experimental investigational medicinal product that is likely to interfere with the study medication. note: pregnancy and breastfeeding are not exclusions for entry

- covid-19 diagnosed > 5 days prior to randomization; - active tuberculosis; - need for concomitant drugs that are contraindicated with the use of chloroquine/hydroxychloroquine; - qtcf interval > 480 ms; - known glomerular filtration rate < 10 ml/min; - known with glucose-6-phosphate dehydrogenase deficiency (g6pd); - previous adverse drug reaction to investigational product; - concurrent involvement in other research or use of chloroquine, hydroxychloroquine or any other 4-aminoquinolone or another experimental investigational medicinal product that is likely to interfere with the study medication. note: pregnancy and breastfeeding are not exclusions for entry